| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 16.2 | 11.8 |
| Gross profit | 12.7 | 9.0 |
| Profit before tax | -7.0 | -8.7 |
| Net income | -7.0 | -8.7 |
| EPS (diluted, $ a share) | $-0.34 | $-0.64 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +37.7% |
|---|---|
| Gross margin | 78.5% |
| Operating margin | -46.9% |
10-Q filed with the SEC, NYSE: SI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Shoulder Innovations, Inc.: key numbers
- Share price
- $20.45Close, Nov 16
- Market cap
- $428M
- Shares outstanding
- 20.92MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Shoulder Innovations, Inc.
All →Shoulder Innovations Earnings Call: Key Takeaways
Shoulder Innovations delivered a strong Q3 2026 with 38% revenue growth, raising full-year guidance on robust surgeon adoption and a broadening product pipeline despite typical seasonal headwinds.
- Call
- Nov 5, 2026, 4:30 PM ET
Shoulder Innovations Financial Results
Shoulder Innovations reported Q3 2026 revenue of $16.2 million, a 38% year-over-year increase driven by higher implant system sales and surgeon adoption. The company raised its full-year 2026 revenue guidance to a range of $68 million to $70 million and highlighted the commercial launch of its N-22 humeral head.
“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving.”
Rob Ball, CEO of Shoulder Innovations
“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”
Rob Ball, CEO of Shoulder Innovations
Shoulder Innovations Product Launch
Shoulder Innovations announced the limited user release and commercial launch of InSet Go, its next-generation glenoid implant for anatomic shoulder arthroplasty. The launch follows the successful completion of the first surgical case and aims to improve procedural efficiency while maintaining the company's clinically-proven design for implant stability.